BBOT reports Q2 2026 net loss of $56.5M; cash runway into 2028

BridgeBio Oncology Therapeutics, Inc.

Net loss widened to $56.5M in Q2 2026 vs $28.4M in Q2 2025; R&D up to $49.2M from $27.4M.
G&A rose to $11.0M from $2.7M, reflecting standalone operations, de-SPAC, and one-time severance.
Cash, equivalents and marketable securities $344.1M as of June 30, 2026; expected runway into 2028.
Initiated dosing of BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combos; also BBO-8520 + BBO-10203.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.